BRAF Clinical Trials

2 recruiting

BRAF Trials at a Glance

22 actively recruiting trials for braf are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Nashville, Shanghai, and Baltimore. Lead sponsors running braf studies include Novartis Pharmaceuticals, Fore Biotherapeutics, and City of Hope Medical Center.

Browse braf trials by phase

Treatments under study

About BRAF Clinical Trials

Looking for clinical trials for BRAF? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new BRAF trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about BRAF clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 2

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco96 enrolled5 locationsNCT07110246
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Early Phase 1

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

BRAF V600E Mutation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins24 enrolled1 locationNCT06610682
Recruiting
Phase 1

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic CarcinomaBRAF NP_004324.2:p.V600EBRAF V600K Mutation Present
City of Hope Medical Center6 enrolled3 locationsNCT03975231
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Solid TumorsHGGCancer Harboring BRAF Alterations+1 more
Fore Biotherapeutics254 enrolled67 locationsNCT05503797
Recruiting
Phase 2

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

BRAF V600E
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Novartis Pharmaceuticals40 enrolled8 locationsNCT05868629
Recruiting
Early Phase 1

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IVBRAF V600 MutationMelanoma Stage III
H. Lee Moffitt Cancer Center and Research Institute50 enrolled1 locationNCT04741997
Recruiting
Phase 1

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Metastatic MelanomaBRAF Gene Mutation
Rina Plattner30 enrolled4 locationsNCT04903119
Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals110 enrolled68 locationsNCT06262919
Recruiting
Not Applicable

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Metastatic Colorectal CancerBRAF V600E Mutation Positive
UNICANCER400 enrolled45 locationsNCT05639413
Recruiting
Phase 2

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Colorectal NeoplasmsBRAFRAS
Zhejiang University70 enrolled1 locationNCT07257653
Recruiting
Phase 1

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Thyroid CancerBRAF Mutation-Related TumorsAnaplastic Thyroid Cancer
UNC Lineberger Comprehensive Cancer Center12 enrolled2 locationsNCT06902376
Recruiting
Phase 2

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
Northwestern University43 enrolled1 locationNCT05576896
Recruiting
Phase 2

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Melanoma BRAF V600E/K MutatedMelanoma and Brain Metastases
Grupo Español Multidisciplinar de Melanoma33 enrolled18 locationsNCT06887088
Recruiting
Phase 2

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

BRAF V600 Colorectal Cancer
Sun Yat-sen University20 enrolled1 locationNCT07150247
Recruiting
Phase 1Phase 2

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer

RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.72 enrolled27 locationsNCT07044908
Recruiting

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd50 enrolled7 locationsNCT07022457
Recruiting

A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal CancerBRAF V600 Mutation
Fudan University100 enrolled1 locationNCT06749015
Recruiting
Phase 2

Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

BRAF V600E Mutation PositiveAmeloblastoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University12 enrolled1 locationNCT06653517